Holzgerlingen, Germany, November 10, 2015 -- Curetis N.V. (the “Company” and, together with Curetis AG, "Curetis"), a developer of next-level molecular diagnostic solutions, today announces the completion of its initial public offering, which was launched on October 28, 2015 (the “IPO” or the “Offering”). The listing of and first trading of all of Curetis’ shares (the “Shares”) (on an “as-if-and-when-issued” basis) on Euronext in Amsterdam and Euronext in Brussels is expected to commence on November 11, 2015 (the “First Trading Date”) under the ticker symbol “CURE”.